Research News on Bone Health
-
Vitamin D Levels May Be Reason Some Women Benefit from Zometa Added to Chemo
New results from a large study suggest that postmenopausal women diagnosed with early-stage breast cancer who had adequate vitamin D levels got more benefits from Zometa combined with chemotherapy than women who had low vitamin D levels.
-
Xgeva Better Than Zometa at Reducing Risk of Bone Problems in Women with Metastatic Disease
Research suggests that Xgeva is better than Zometa at reducing the risk of bone complication and improves quality of life more in women diagnosed with metastatic breast cancer that has spread to the bones.
-
Oral Bisphosphonates Don’t Seem to Reduce Recurrence Risk
Two studies found that two oral bisphosphonates didn't reduce recurrence risk for women diagnosed with early-stage breast cancer.
-
Zometa Can Help Reduce Recurrence Risk of Hormone-Receptor-Positive Disease
Results from three studies all suggest that Zometa can help reduce the risk of cancer recurrence when it's started right after surgery to treat hormone-receptor-positive early-stage breast cancer in postmenopausal and older premenopausal women.
-
Xgeva More Likely to Cause Osteonecrosis of the Jaw in Women Diagnosed with Advanced-Stage Breast Cancer
Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
FDA Warning: Reclast May Cause Severe Kidney Problems
On Sept. 1, 2011 the U.S. Food and Drug Administration warned doctors and patients that Reclast may cause severe kidney problems.
-
Long-Term Bisphosphonate Use Linked to Atypical Fracture Risk
Women who take bisphosphonates for more than 5 years have a higher risk of breaking a leg bone in an unusual spot.
-
Government Experts Release New Osteoporosis Screening Guidelines
The U.S. Preventive Services Task Force has released new guidelines that call for more women to be screened for osteoporosis.
-
Xgeva Better Than Zometa at Reducing Risk of Breast Cancer Bone Problems
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is better than Zometa at lengthening the time before bone complications develop in women diagnosed with breast cancer that has spread to the bones.
